Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a white blood cell booster heal a rare skin emergency?

NCT ID NCT02739295

Disease control Sponsor: University of Liege Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether G-CSF (a drug that boosts white blood cells) can help heal toxic epidermal necrolysis, a rare but severe skin reaction. Ten patients were randomly assigned to receive G-CSF or a placebo for five days. Researchers measured how fast the skin healed and looked at immune cell changes in the skin.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
G-CSF (Neupogen)
What this could lead to
If it works, G-CSF could speed up skin healing and improve outcomes for people with this rare, life-threatening skin condition.
What could go wrong
This is a very small trial (10 people) and results may not apply to all patients. G-CSF can cause side effects like bone pain or spleen enlargement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

10 people

The number who actually took part.

Started

Jul 2016

Finished

Mar 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Toxic epidermal necrolysis with SCORTEN 1 to 5 at admission Exclusion Criteria: * Toxic epidermal necrolysis with SCORTEN 6 or 7 at admission * Hypercoagulable state * Cardiac or peripheral arterial disease * Active malignancy * Myelodysplastic syndrome or hematological malignancy * Fructose intolerance * Pregnancy * Patient refusal

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stevens-Johnson syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Stevens-Johnson syndrome toxic epidermal necrolysis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stevens-Johnson syndrome

Contacts and locations

Locations

  • Burn Centre of the University Hospital of Liège

    Liège, 4000, Belgium

  • IMTR Burn Centre

    Loverval, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.